KRAS and non-small cell lung carcinoma: Although two different meta-analyses concluded that KRAS mutation is a negative prognosticator in LADC [9,10], the most comprehensive study of more than 1500 NSCLC patients (including 300 KRAS-mutant cases) from four trials of adjuvant chemotherapy (CHT) reported that KRAS mutation had no clear prognostic or predictive relevance with regards to response to CHT [11].